Spinal metastatic epiduritis is frequent because the spine is the predominant site of skeletal metastases, accounting for up to 50% of all bone localizations1,2. Clinical presentation typically includes severe pain with marked impairment of quality of life, followed by rapidly progressive neurological deficits that may end in paraplegia or tetraplegia, depending on the level of involvement3,4. Radiotherapy is the standard of care for metastatic epidural spinal cord compression, while decompressive and stabilizing surgery benefits selected patients with adequate performance status and expected survival5,6. Stereotactic ablative radiotherapy can improve local control in selected cases but is limited by spinal cord tolerance and planning complexity7. Local recurrence or progression after radiotherapy is frequent, and re-irradiation is limited by cumulative dose constraints, often resulting in therapeutic dead-ends for patients with persistent pain or progressive neurological compromise6,7. In this context, a local nonthermal technique capable of achieving pain relief, decompression, and tumor control near critical neural structures is needed.
Electrochemotherapy (ECT) combines the administration of cytotoxic agents, most commonly bleomycin, with short high-voltage electric pulses that transiently increase plasma membrane permeability and enhance intracellular drug uptake8,9. ECT is minimally invasive, nonthermal, and relatively tumor-selective, and has shown encouraging results for cutaneous, subcutaneous, and deep-seated tumors located close to critical structures10,11. A recent clinical series reported an MRI objective response rate of 77% at 1 month and 66.5% at 3 months after percutaneous spinal ECT for radiotherapy-resistant epidural spinal cord compression. Pain also decreased markedly, with the median Numeric Rating Scale pain score decreasing from 7 at baseline to 1 at 1 month. Irreversible neurological deficits still occurred in a subset of patients12. These events highlight the central role of electric field distribution: small changes in electrode geometry or tissue properties can markedly alter the treated volume, exposing patients to both undertreatment and overtreatment13,14. Numerical studies suggest that patient-specific modeling can optimize electrode placement and improve coverage of vertebral tumors while limiting exposure of neural structures15,16.
Several research planning frameworks have been proposed for electroporation therapies, but routine clinical implementation remains limited by meshing/parameter requirements and computation time17,18,19,20,21. Recent work by Sutter and Poignard supports a peri-procedural, imaging-driven simulation workflow compatible with clinical constraints and shows that incomplete electric-field isodose coverage accurately correlates with local failure after IRE22,23. This protocol builds on the same simulation framework.
The aim of this article is therefore to provide a reproducible, patient-specific workflow for electric field modeling and validation in spinal ECT, based on real clinical imaging datasets and delivered electrode configurations. In its current form, this workflow is best suited for pre-procedural planning to optimize electrode positioning, as segmentation and model preparation times remain a limitation for routine intra-procedural adjustment. It is intended as a methodological framework rather than a hypothesis-driven efficacy study and is designed for interventional oncology and spine teams already performing or planning percutaneous CT-guided ECT in epidural metastases and other anatomically complex settings.